Tests and what they answer
Karyotyping detects chromosomal rearrangements, FISH targets specific loci, PCR detects fusion transcripts and mutations, and NGS panels assess many genes at once. The right test depends on the suspected disease and the clinical question.
Related: Haematology → · Dr. Sachita Baniya profile → · All conditions →
Why results change treatment
In AML, mutations such as FLT3, IDH1/2, NPM1 and TP53 inform risk and targeted therapy. In CML, BCR-ABL1 monitoring guides TKI therapy. In CLL, TP53 status influences treatment. In myeloma, FISH identifies high-risk disease. Results should be interpreted with the full clinical picture.
- Diagnostic and prognostic mutation panels
- Fusion gene detection
- FISH for translocations and deletions
- Molecular monitoring of treatment response
- Repeat testing for resistance or progression
Access
Molecular testing is coordinated through the treating institution and accredited laboratories. Dr. Baniya consults at Kathmandu Neurology Clinic & Cognitive Center, Durbar Marg, and also practises at Kathmandu Cancer Center (KCC) Nepal, Civil Service Hospital, Kathmandu, and Advanced Care Hospital.